Rpg Life Sciences is a pharmaceutical company in Healthcare. Market cap ₹4,590.8 Cr, quarterly revenue ₹180–195 Cr. Maintains operating margins of 20–22%.
Generated analysis · source review pending
Generated analysis · source review pending
2,528 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Consolidated figures
| Ratio | Mar 2026 |
|---|---|
| Margins | |
| Gross margin % | 64.4% |
| EBITDA margin % | 20.8% |
| EBIT margin % | 17.8% |
| PAT margin % | 16.3% |
| Working capital | |
| Receivable days | 60 |
| Inventory days | 179 |
| Payable days | 141 |
| NWC days | 99 |
| Leverage | |
| Current ratio | 3.52 |
| Debt to EBITDA | 0.14 |
| Debt to equity | 0.03 |
| Interest coverage | 169.9 |
| Asset turnover | 0.89 |
| Return ratios | |
| Return on assets % | 14.5% |
| Return on capital employed % | 23.9% |
| Return on equity % | 19% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
| Holder (%) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72.81% | 72.81% | 72.81% | 72.81% | 72.81% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | |
| 0.46% | 0.56% | 0.89% | 1.14% | 1.35% | 1.3% | 1.45% | 1.35% | 1.11% | 1% | 0.87% | 0.95% | |
| 3.59% | 3.79% | 4.19% | 4.63% | 5.45% | 6.06% | 6.14% | 6.48% | 6.7% | 7.04% | 7.45% | 8.67% | |
| 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| 23.14% | 22.84% | 22.11% | 21.42% | 20.39% | 19.69% | 19.46% | 19.22% | 19.24% | 19.01% | 18.73% | 17.43% | |
| No. of shareholders | — | — | — | — | — | — | — | — | 26,657 | 25,905 | 25,282 | 23,886 |
Promoter holding up 0.14 percentage points since Sep 2023.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 30 Apr 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | NSE | Buy | 1,09,801 | ₹2,257.02 | ₹24.78 Cr |
| 30 Apr 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | NSE | Sell | 1,09,801 | ₹2,258.73 | ₹24.80 Cr |
| 21 Sept 2021 | XTX MARKETS LLP | Bulk | NSE | Sell | 1,36,929 | ₹731.47 | ₹10.02 Cr |
| 21 Sept 2021 | XTX MARKETS LLP | Bulk | NSE | Buy | 1,35,708 | ₹730.53 | ₹9.91 Cr |
| 3 Sept 2021 | XTX MARKETS LLP | Bulk | NSE | Buy | 89,624 | ₹596.00 | ₹5.34 Cr |
| 3 Sept 2021 | XTX MARKETS LLP | Bulk | NSE | Sell | 85,613 | ₹597.08 | ₹5.11 Cr |
| 1 Sept 2021 | XTX MARKETS LLP | Bulk | NSE | Buy | 1,62,323 | ₹566.91 | ₹9.20 Cr |
| 1 Sept 2021 | XTX MARKETS LLP | Bulk | NSE | Sell | 1,59,973 | ₹568.09 | ₹9.09 Cr |
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM | ₹1,61,325 Cr | ₹1,76,123 Cr | ₹15,723 Cr | ₹5,191 Cr | 32.6% | ₹2,181 Cr | 15.3% | 14.5% | 27.1% | 163 |
| Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE | ₹1,14,284 Cr | ₹1,26,053 Cr | ₹28,592 Cr | ₹8,316 Cr | 31.2% | ₹4,513 Cr | 18.9% | 23.4% | 19.7% | 212 |
| Laurus Labs LimitedLAURUSLABSLAURUSLABS | ₹1,07,176 Cr | ₹1,09,573 Cr | ₹7,270 Cr | ₹2,034 Cr | 26.1% | ₹1,093 Cr | 13.1% | 21.3% | 18.2% | 263 |
| Mankind Pharma LimitedMANKINDMANKIND | ₹1,04,696 Cr | ₹1,11,007 Cr | ₹14,738 Cr | ₹3,827 Cr | 25.3% | ₹2,068 Cr | 13.6% | 14.2% | 12.5% | 117 |
| Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA | ₹97,389 Cr | ₹1,05,065 Cr | ₹34,935 Cr | ₹7,085 Cr | 20.3% | ₹3,713 Cr | 10.4% | 14.7% | 9.9% | 252 |
| Lupin LimitedLUPINLUPIN | ₹92,866 Cr | ₹98,777 Cr | ₹29,967 Cr | ₹9,538 Cr | 31.5% | ₹5,529 Cr | 19.2% | 34.2% | 26.9% | 181 |
| Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK | ₹65,781 Cr | ₹65,781 Cr | ₹17,737 Cr | ₹4,797 Cr | 26.9% | ₹1,496 Cr | 8% | 37.8% | 0% | 83 |
| Alkem Laboratories LimitedALKEMALKEM | ₹62,431 Cr | ₹64,055 Cr | ₹15,081 Cr | ₹3,032 Cr | 20.4% | ₹2,158 Cr | 16% | 21.5% | 17.8% | 152 |
| Biocon LimitedBIOCONBIOCON | ₹60,413 Cr | ₹75,238 Cr | ₹17,321 Cr | ₹3,536 Cr | 20.4% | ₹495 Cr | 2.2% | 3.9% | 1.4% | 85 |
| Abbott India LimitedABBOTINDIAABBOTINDIA | ₹56,901 Cr | — | ₹4,310 Cr | ₹921 Cr | 27.3% | ₹691 Cr | 22.4% | 44.1% | 34.5% | 110 |
| Ipca Laboratories LimitedIPCALABIPCALAB | ₹49,299 Cr | ₹50,003 Cr | ₹10,126 Cr | ₹2,232 Cr | 20.5% | ₹1,310 Cr | 12.3% | 17.8% | 15.2% | 308 |
| Gland Pharma LimitedGLANDGLAND | ₹47,428 Cr | ₹47,671 Cr | ₹6,725 Cr | ₹1,751 Cr | 25.3% | ₹1,129 Cr | 16% | 14.8% | 10.5% | 255 |
Documents link to external sources (exchange filings, company investor pages).
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Update On Business Transfer Agreement By RPGAP
Update On Investment And Shareholder Agreement
Outcome Of Investors Meet
Investors Meet
Announcement under Regulation 30 (LODR)-Investor Presentation
| Date | Category | Subject | Filing |
|---|---|---|---|
| 30 Sept 2026, 4:40 pm | Company Update Newspaper Publication | Announcement under Regulation 30 (LODR)-Newspaper Publication | |
| 28 Sept 2026, 2:13 pm | Insider Trading / SAST Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 | |
| 17 Sept 2026, 5:08 pm | Company Update Analyst / Investor Meet | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | |
| 15 Sept 2026, 11:30 pm | Company Update General | Update On Business Transfer Agreement By RPGAP | |
| 9 Sept 2026, 10:50 pm | Company Update General | Update On Investment And Shareholder Agreement | |
| 4 Sept 2026, 8:58 am | Company Update General | Outcome Of Investors Meet | |
| 3 Sept 2026, 11:52 am | Company Update General | Investors Meet | |
| 2 Sept 2026, 10:34 pm | Company Update Investor Presentation | Announcement under Regulation 30 (LODR)-Investor Presentation |
2 schemes
| Shares | ||||||
|---|---|---|---|---|---|---|
| (Investment Manager for Motilal Oswal Mutual Fund) | Motilal Oswal Mutual Fund | 118 | 0.03 | 0.07% | 0.001% | -0 |
| (Investment Manager for Motilal Oswal Mutual Fund) | Motilal Oswal Mutual Fund | 13 | 0 | 0.01% | 0% | -0 |
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2026 |
|---|---|
| Revenue | 708 |
| COGS | 252 |
| Gross profit | 455 |
| 308 | |
| 147 | |
| OPM % | 20.8% |
| Depreciation | 21 |
| Interest | 1 |
| 29 | |
| Profit before tax | 154 |
| Tax | 39 |
| Tax % | 25.3% |
| PAT | 115 |
| PAT margin % | 16.3% |
| EPS (₹) | 18.1 |
| EPS adjusted (₹) | 69.6 |
| 132.7% | |
| Annual report | Annual report for Mar 2026 |
| ₹ Cr | Mar 2026 |
|---|---|
| Equity capital | 13 |
| Reserves | 592 |
| 20 | |
| 168 | |
| Total equity & liabilities | 793 |
| 197 | |
| CWIP | 20 |
| Investments | 85 |
| 491 | |
| Total assets | 793 |
| ₹ Cr | Mar 2026 |
|---|---|
| 57 | |
| 86 | |
| -21 | |
| Net cash flow | 122 |
| Free cash flow | -9 |
| CFO / Operating profit % | 38.4% |